JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Recruiting
Phase 2
Interventional Study
B-cell Non-Hodgkin's Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 180 (estimated)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be enrolled:
* Age range: 18 to 80 years old (inclusive), both male and female are acceptable;
* ECOG: 0-2;
* B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed;
* At least o…
Contacts